• Central Control of Opioid-Induced Mechanical Hypersensitivit

  2026-06-12

  Yin et al. (2024) identify a brain-to-spinal opioid pathway that governs morphine-induced mechanical hypersensitivity (OIH) and tolerance in mice, revealing the central mechanisms underlying these clinically significant opioid side effects. This work advances the understanding of pain modulation, with implications for refining opioid receptor pharmacology and developing targeted interventions.

• Co-Targeting BRD4 and RAC1 Disrupts Breast Cancer Oncogenic

  2026-06-12

  This study demonstrates that simultaneous inhibition of BRD4 and RAC1 disrupts key oncogenic signaling pathways in distinct breast cancer subtypes, reducing growth, stemness, and tumorigenicity. The findings highlight the therapeutic promise of dual-targeting strategies that modulate epigenetic and signaling mechanisms.

• Sulforaphane Inhibits NLRP3 Inflammasome in Ulcerative Colit

  2026-06-11

  This study demonstrates that sulforaphane, a natural isothiocyanate, significantly reduces oxidative stress and suppresses NLRP3 inflammasome activation in a dextran sodium sulfate-induced mouse model of ulcerative colitis. These mechanistic findings position sulforaphane as a promising tool for dissecting inflammatory pathways and oxidative stress responses in disease models.

• SmD2 Acetylation Controls PARP Inhibitor Sensitivity in HCC

  2026-06-11

  This study uncovers how acetylation of spliceosome core protein SmD2 regulates DNA repair and increases the sensitivity of hepatocellular carcinoma (HCC) cells to PARP inhibitors. These insights reveal a mechanistic link between spliceosomal regulation and therapeutic vulnerability in BRCA-proficient HCC, suggesting new strategies for targeted cancer therapies.

• 2-Deoxy-D-glucose: Glycolysis Inhibition and Immunometabolic

  2026-06-10

  Explore the multifaceted roles of 2-Deoxy-D-glucose (2-DG) in glycolysis inhibition, immunometabolic modulation, and translational research. This article uniquely dissects mechanistic insights and protocol nuances, empowering advanced researchers in cancer, immunology, and antiviral fields.

• Muscle-Derived BDNF and MMPs Orchestrate NMJ Postsynaptic As

  2026-06-10

  This study uncovers how muscle-generated BDNF, through spatially regulated vesicular trafficking and proteolytic processing, governs the early formation of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings reveal critical roles for localized, calcium-dependent BDNF release and matrix metalloproteinase (MMP) activity in orchestrating synaptic development, with implications for mechanistic investigations using MMP inhibitors such as Batimastat (BB-94).

• Gepotidacin (GSK2140944): A Novel Oral Antibiotic Targeting

  2026-06-09

  The reference study introduces gepotidacin (GSK2140944) as a first-in-class, oral triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea, addressing rising antimicrobial resistance. Its unique dual inhibition of bacterial DNA gyrase and topoisomerase IV demonstrates potent activity against multidrug-resistant pathogens, with promising clinical data supporting its further development.

• JHU-083: Precision Glutaminase Antagonism in Neuro-Redox Mod

  2026-06-09

  JHU-083, a 6-diazo-5-oxo-L-norleucine precursor, transforms glutaminase pathway research in neurological and oxidative stress models. Its high selectivity and flexible solubility profile streamline workflows for experimental cerebral malaria and glutamate excitotoxicity studies. Uncover the application-driven edge of JHU-083 with protocol guidance and troubleshooting based on the latest research.

• LINC01278 Suppresses Uveal Melanoma via mTOR Pathway Inhibit

  2026-06-08

  The referenced study identifies LINC01278 as a tumor-suppressing lncRNA that induces autophagy and inhibits uveal melanoma progression by downregulating the mTOR signaling pathway. These findings offer new mechanistic insight into lncRNA-driven autophagy regulation, with implications for biomarker development and targeted therapy strategies.

• TG003 Cdc2-like kinase Inhibitor: Mechanism, Evidence & Use

  2026-06-08

  TG003 is a potent Cdc2-like kinase inhibitor that precisely modulates splice site selection via Clk1/2/4 inhibition. It enables mechanistic dissection of alternative splicing in disease models, including platinum-resistant ovarian cancer and exon-skipping therapy research. Supplied by APExBIO, TG003 is a benchmark tool for studying SR protein phosphorylation and mRNA splicing regulation.

• Microfluidized Dextran Microgels Enable Oral Colon Cancer Th

  2026-06-07

  This study demonstrates a dual-targeted microgel system for delivering cisplatin and SPION-loaded lipid nanoparticles to the colon via oral administration. The innovation lies in hierarchical targeting and enzymatic release, resulting in improved local drug accumulation and significant suppression of colorectal cancer progression.

• Methicillin Sodium Salt: Advanced Assays and Resistance Prof

  2026-06-06

  Explore the science and protocols behind Methicillin sodium salt as a bacterial cell wall synthesis inhibitor. This in-depth guide highlights advanced applications, resistance modeling, and the latest screening innovations for Staphylococcus aureus infection research.

• Gepotidacin (GSK2140944): A New Mechanism to Counter UTI and

  2026-06-05

  The referenced study introduces Gepotidacin (GSK2140944) as a first-in-class oral antibiotic targeting bacterial type II topoisomerases, with promising activity against multidrug-resistant uropathogens and Neisseria gonorrhoeae. This mechanism offers a vital new approach for antibacterial research, filling a longstanding gap in oral therapy for urinary tract infections and gonorrhea.

• AP20187: Precision Chemical Inducer of Dimerization in Resea

  2026-06-05

  AP20187 offers unmatched precision in conditional gene expression through programmable dimerization of engineered fusion proteins. Its robust performance, high solubility, and integration into cutting-edge signaling pathway studies make it the gold standard for regulated cell therapy and metabolic research.

• SIRT1 Activation by Resveratrol Restores Mitochondrial Bioge

  2026-06-04

  This study elucidates how SIRT1, a NAD+-dependent deacetylase, regulates mitochondrial biogenesis and quality control in N2a neuroblastoma cells challenged with the neurotoxic prion fragment PrP106–126. The research demonstrates that SIRT1 activation, particularly by resveratrol, counteracts prion-induced mitochondrial dysfunction and apoptosis via the PGC-1α/TFAM pathway, suggesting new therapeutic angles for prion diseases.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page